

James K Liao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2240879/publications.pdf>

Version: 2024-02-01

106
papers

15,916
citations

36303

51
h-index

33894

99
g-index

107
all docs

107
docs citations

107
times ranked

15994
citing authors

#	ARTICLE	IF	CITATIONS
1	Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors. <i>Circulation</i> , 1998, 97, 1129-1135.	1.6	1,736
2	PLEIOTROPIC EFFECTS OF STATINS. <i>Annual Review of Pharmacology and Toxicology</i> , 2005, 45, 89-118.	9.4	1,574
3	Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase. <i>Journal of Biological Chemistry</i> , 1998, 273, 24266-24271.	3.4	941
4	Pleiotropic Effects of Statins on the Cardiovascular System. <i>Circulation Research</i> , 2017, 120, 229-243.	4.5	808
5	Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. <i>Trends in Molecular Medicine</i> , 2008, 14, 37-44.	6.7	522
6	Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase. <i>Journal of Biological Chemistry</i> , 1995, 270, 319-324.	3.4	473
7	Rho-Kinase Mediates Hypoxia-Induced Downregulation of Endothelial Nitric Oxide Synthase. <i>Circulation</i> , 2002, 106, 57-62.	1.6	459
8	Rho GTPases, Statins, and Nitric Oxide. <i>Circulation Research</i> , 2005, 97, 1232-1235.	4.5	434
9	Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. <i>Journal of Clinical Investigation</i> , 2001, 108, 1429-1437.	8.2	429
10	Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy. <i>Circulation</i> , 2003, 108, 839-843.	1.6	387
11	Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase. <i>Journal of Biological Chemistry</i> , 1997, 272, 31725-31729.	3.4	354
12	3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27. <i>Journal of Biological Chemistry</i> , 1999, 274, 21926-21931.	3.4	352
13	Inhibition of Rho Kinase (ROCK) Leads to Increased Cerebral Blood Flow and Stroke Protection. <i>Stroke</i> , 2005, 36, 2251-2257.	2.0	351
14	Rho Kinase (ROCK) Inhibitors. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 17-24.	1.9	344
15	Physiological role of ROCKs in the cardiovascular system. <i>American Journal of Physiology - Cell Physiology</i> , 2006, 290, C661-C668.	4.6	339
16	Linking endothelial dysfunction with endothelial cell activation. <i>Journal of Clinical Investigation</i> , 2013, 123, 540-541.	8.2	333
17	Isoprenoids as mediators of the biological effects of statins. <i>Journal of Clinical Investigation</i> , 2002, 110, 285-288.	8.2	327
18	Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1842-1847.	2.4	312

#	ARTICLE	IF	CITATIONS
19	Requirement of Rac1 in the development of cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7432-7437.	7.1	268
20	Fingolimod provides long-term protection in rodent models of cerebral ischemia. Annals of Neurology, 2011, 69, 119-129.	5.3	249
21	Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2005, 96, 24-33.	1.6	243
22	Beyond lipid lowering: the role of statins in vascular protection. International Journal of Cardiology, 2002, 86, 5-18.	1.7	241
23	Safety and Efficacy of Statins in Asians. American Journal of Cardiology, 2007, 99, 410-414.	1.6	218
24	Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation, 2002, 110, 285-288.	8.2	210
25	Evidence for Statin Pleiotropy in Humans. Circulation, 2009, 119, 131-138.	1.6	208
26	Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. Journal of Clinical Investigation, 2010, 120, 3280-3295.	8.2	206
27	Decreased Perivascular Fibrosis but Not Cardiac Hypertrophy in ROCK1 +/Δ Haploinsufficient Mice. Circulation, 2005, 112, 2959-2965.	1.6	195
28	Estrogens and Glucocorticoids Inhibit Endothelial Vascular Cell Adhesion Molecule-1 Expression by Different Transcriptional Mechanisms. Circulation Research, 2000, 87, 19-25.	4.5	171
29	The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis. Pharmacological Reviews, 2015, 67, 103-117.	16.0	161
30	Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery Disease. Circulation Research, 2006, 99, 1426-1432.	4.5	155
31	ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. Journal of Clinical Investigation, 2008, 118, 1632-1644.	8.2	152
32	Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends in Pharmacological Sciences, 2011, 32, 167-173.	8.7	139
33	Endothelial Nitric Oxide Synthase-Dependent Cerebral Blood Flow Augmentation by L-Arginine After Chronic Statin Treatment. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 709-717.	4.3	134
34	Elevated Angiotensin II Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding. Circulation, 2016, 134, 141-152.	1.6	127
35	Long-term statin use and psychological well-being. Journal of the American College of Cardiology, 2003, 42, 690-697.	2.8	121
36	Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis, 2009, 205, 517-521.	0.8	119

#	ARTICLE	IF	CITATIONS
37	Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease. <i>Current Pharmaceutical Design</i> , 2009, 15, 3108-3115.	1.9	100
38	Rho Kinases and Cardiac Remodeling. <i>Circulation Journal</i> , 2016, 80, 1491-1498.	1.6	95
39	Increased Rho Kinase Activity in a Taiwanese Population With Metabolic Syndrome. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1619-1624.	2.8	93
40	RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. <i>Stroke</i> , 2017, 48, 187-194.	2.0	86
41	The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 471-481.	2.9	86
42	Roles of Rho-Associated Kinase and Oxidative Stress in the Pathogenesis of Aortic Stiffness. <i>Journal of the American College of Cardiology</i> , 2007, 49, 698-705.	2.8	83
43	Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 279, H2649-H2657.	3.2	82
44	FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. <i>FASEB Journal</i> , 2013, 27, 1439-1449.	0.5	82
45	Statins Exert the Pleiotropic Effects Through Small GTP-Binding Protein Dissociation Stimulator Upregulation With a Resultant Rac1 Degradation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1591-1600.	2.4	73
46	Comparison of Effects of Rosuvastatin (10 mg) Versus Atorvastatin (40 mg) on Rho Kinase Activity in Caucasian Men With a Previous Atherosclerotic Event. <i>American Journal of Cardiology</i> , 2009, 103, 437-441.	1.6	69
47	Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR ^{-/-} mice. <i>FASEB Journal</i> , 2008, 22, 3561-3570.	0.5	67
48	Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. <i>JCI Insight</i> , 2017, 2, .	5.0	55
49	Emerging views of statin pleiotropy and cholesterol lowering. <i>Cardiovascular Research</i> , 2022, 118, 413-423.	3.8	54
50	The Pleiotropic Effects of Statins “From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. <i>Current Vascular Pharmacology</i> , 2019, 17, 222-232.	1.7	54
51	Secondary Prevention of Stroke and Transient Ischemic Attack. <i>Circulation</i> , 2007, 115, 1615-1621.	1.6	53
52	A Method for Measuring Rho Kinase Activity in Tissues and Cells. <i>Methods in Enzymology</i> , 2008, 439, 181-189.	1.0	53
53	Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. <i>Current Opinion in Pharmacology</i> , 2010, 10, 116-121.	3.5	53
54	Tumor necrosis factor- α levels and non-surgical bleeding in continuous-flow left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 107-115.	0.6	53

#	ARTICLE	IF	CITATIONS
55	Increased leukocyte ROCK activity in patients after acute ischemic stroke. <i>Brain Research</i> , 2009, 1257, 89-93.	2.2	48
56	Statin Therapy for Cardiac Hypertrophy and Heart Failure. <i>Journal of Investigative Medicine</i> , 2004, 52, 248-253.	1.6	45
57	Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. <i>Journal of Hypertension</i> , 2011, 29, 373-379.	0.5	44
58	ROCK as a therapeutic target for ischemic stroke. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1167-1177.	2.8	44
59	Potential serum biomarkers in the pathophysiological processes of stroke. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 173-185.	2.8	41
60	Increased Rho kinase activity in congestive heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 965-973.	7.1	40
61	Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive <i><i>Pcd10/Ccm3</i></i> Disease. <i>Stroke</i> , 2019, 50, 738-744.	2.0	40
62	The inhibition of endothelial activation by unsaturated fatty acids. <i>Lipids</i> , 1999, 34, S191-S194.	1.7	34
63	Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. <i>Scientific Reports</i> , 2016, 6, 24578.	3.3	32
64	Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina. <i>Atherosclerosis</i> , 2012, 221, 521-526.	0.8	30
65	Serine-threonine kinase ROCK2 regulates germinal center B cell positioning and cholesterol biosynthesis. <i>Journal of Clinical Investigation</i> , 2020, 130, 3654-3670.	8.2	26
66	ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L736-L746.	2.9	25
67	Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 47-62.	3.4	25
68	Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets. <i>Cardiovascular Research</i> , 2017, 113, 1307-1317.	3.8	22
69	A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. <i>Translational Stroke Research</i> , 2020, 11, 365-376.	4.2	22
70	Squalene Synthase Inhibitor Lapaquistat Acetate. <i>Circulation</i> , 2011, 123, 1925-1928.	1.6	21
71	Critical Role of Exogenous Nitric Oxide in ROCK Activity in Vascular Smooth Muscle Cells. <i>PLoS ONE</i> , 2014, 9, e109017.	2.5	21
72	Neuroprotection Mediated by Upregulation of Endothelial Nitric Oxide Synthase in Rho-Associated, Coiled-Coil-Containing Kinase 2 Deficient Mice. <i>Circulation Journal</i> , 2018, 82, 1195-1204.	1.6	20

#	ARTICLE	IF	CITATIONS
73	Inhibition of Rho-kinase attenuates endothelial leukocyte interaction during ischemia reperfusion injury. <i>Vascular Medicine</i> , 2012, 17, 379-385.	1.5	19
74	Increase in Blood-Brain Barrier (BBB) Permeability Is Regulated by MMP3 via the ERK Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-14.	4.0	19
75	Statins and ischemic stroke. <i>Atherosclerosis Supplements</i> , 2002, 3, 21-25.	1.2	16
76	A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 167, 2813-2819.	1.7	16
77	Association of Rising Violent Crime With Blood Pressure and Cardiovascular Risk: Longitudinal Evidence From Chicago, 2014 2016. <i>American Journal of Hypertension</i> , 2019, 32, 1192-1198.	2.0	15
78	Gene variations of ROCKs and risk of ischaemic stroke: the Women's Genome Health Study. <i>Clinical Science</i> , 2014, 126, 829-835.	4.3	14
79	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. <i>Current Atherosclerosis Reports</i> , 2009, 11, 243-244.	4.8	13
80	Cardiology Consultation in the Emergency Department Reduces Re-hospitalizations for Low-Socioeconomic Patients with Acute Decompensated Heart Failure. <i>American Journal of Medicine</i> , 2017, 130, 1112.e17-1112.e31.	1.5	13
81	Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 79, 180-186.	1.9	12
82	Regulator of G Protein Signaling 5 Maintains Brain Endothelial Cell Function in Focal Cerebral Ischemia. <i>Journal of the American Heart Association</i> , 2020, 9, e017533.	3.7	12
83	Rho Kinase regulates neutrophil NET formation that is involved in UVB-induced skin inflammation. <i>Theranostics</i> , 2022, 12, 2133-2149.	10.0	10
84	MnTBAP stimulates angiogenic functions in endothelial cells through mitofusin-1. <i>Vascular Pharmacology</i> , 2015, 72, 163-171.	2.1	9
85	Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism. <i>Journal of Hypertension</i> , 2019, 37, 1083-1095.	0.5	9
86	MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation. <i>Vascular Pharmacology</i> , 2016, 84, 67-73.	2.1	8
87	Genetically elevated C-reactive protein and ischemic vascular disease. <i>Current Atherosclerosis Reports</i> , 2009, 11, 245-245.	4.8	7
88	Role of statin pleiotropism in acute coronary syndromes and stroke. <i>International Journal of Clinical Practice</i> , Supplement, 2003, , 51-7.	0.3	6
89	Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?. <i>Current Atherosclerosis Reports</i> , 2007, 9, 384-388.	4.8	5
90	Exogenous nitric oxide inhibits Rho-associated kinase activity in patients with angina pectoris: a randomized controlled trial. <i>Hypertension Research</i> , 2015, 38, 485-490.	2.7	5

#	ARTICLE	IF	CITATIONS
91	Challenging Statin Pleiotropy: Preeclampsia. <i>Circulation</i> , 2021, 144, 680-683.	1.6	5
92	Evidence of pleiotropy by statins: Leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors. <i>International Journal of Cardiology</i> , 2014, 176, 250-253.	1.7	4
93	Community Health Workers Reduce Rehospitalizations and Emergency Department Visits for Low-Socioeconomic Urban Patients With Heart Failure. <i>Critical Pathways in Cardiology</i> , 2020, 19, 139-145.	0.5	4
94	Vascular Stiffening Mediated by Rho-Associated Coiled-Coil Containing Kinase Isoforms. <i>Journal of the American Heart Association</i> , 2021, 10, e022568.	3.7	4
95	Relative Lack of Culprit and Obstructive Coronary Lesions in Patients With Acute Ischemic Stroke and Elevated Cardiac Troponin. <i>Circulation</i> , 2016, 133, 1228-1229.	1.6	3
96	Response to Letters Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation". <i>Circulation</i> , 2009, 120, .	1.6	2
97	ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2018, 132, 1739-1739.	1.4	2
98	ROCK Isoforms ROCK 1 and ROCK 2 are Critical for the Development of Pulmonary Fibrosis in Several Different Cell Specific Mechanisms. <i>QJM - Monthly Journal of the Association of Physicians</i> , 0, , .	0.5	1
99	SALAD-BAR : A numerical risk score for hospital admission or emergency department presentation in ambulatory patients with cardiovascular disease. <i>Clinical Cardiology</i> , 2021, 44, 193-199.	1.8	1
100	Statins. , 2007, , 1668-1673.		0
101	Steroid Hormones. , 2007, , 1674-1681.		0
102	Is statin discontinuation an option in patients who have had a stroke?. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 18-19.	2.5	0
103	Acute augmentation of cerebral blood flow by rho-kinase inhibitors in focal cerebral ischemia is dependent on endothelial nitric oxide synthase. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S3-S3.	4.3	0
104	RhoA/Rho-Associated Kinase as Marker of Cardiovascular Health. , 2015, , 1-31.		0
105	RhoA/Rho-Associated Kinase as Marker of Cardiovascular Health. , 2016, , 739-769.		0
106	Interventional Transcatheter Closure Ameliorates the Leukocyte Rho Kinase Activities among Patients with Patent Ductus Arteriosus. <i>Acta Cardiologica Sinica</i> , 2015, 31, 494-9.	0.2	0